Premium
Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
Author(s) -
Yu JinTai,
Wang HuiFu,
Shen XueNing,
Li JieQiong,
Suckling John,
Tan ChenChen,
Wang Yanjiang,
Feng Lei,
Zhang Can,
Tan Lan,
Dong Qiang,
Touchon Jacques,
Gauthier Serge
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.042221
Subject(s) - biomarker , neuroimaging , cerebrospinal fluid , medicine , alzheimer's disease neuroimaging initiative , atrophy , dementia , cognitive decline , disease , pathology , oncology , pathogenesis , alzheimer's disease , amyloid (mycology) , psychiatry , biology , biochemistry
Background It has been documented that β‐amyloid (Aβ) deposition, tau pathology and neuronal degeneration precedes clinical symptoms in autosomal dominant Alzheimer's disease (AD). Since the divergence on pathogenesis between sporadic and familial AD limits the extension of these findings to sporadic AD, where and magnitude of pathologic processes in sporadic AD are of significant importance to clinical management. Method In this longitudinal study, we analyzed data from 982 ADNI participants with abnormal amyloid accumulations who underwent cerebrospinal fluid (CSF) test, brain imaging and cognitive assessments. We compared the levels of clinical outcomes and biomarkers at baseline and the rates of change in follow‐up between different stages of AD. The slope of the regression model over years was applied to estimate rates of change for Aβ deposition, tau alteration, hypometabolism, brain atrophy, and cognitive decline. Result In total 167 healthy controls, 133 patients with preclinical AD, 451 patients with MCI due to AD, and 231 patients with dementia due to AD were studied. The levels of clinical and biomarkers at baseline and their change rates at follow‐up significantly differed among the four groups. In terms of average years, Aβ deposition was observed over a range of 45·6 years for CSF Aβ, and 31·1 years with amyloid imaging, although Aβ markers began to be abnormal at 27·8 years for CSF Aβ and 26·3 years for neuroimaging. When Aβ markers exceeded the threshold, CSF tau and other non‐ Aβ markers started to change, and patients were estimated to take 29·1 years (CSF tau),12·7 years (memory), 12·2 years (hippocampus atrophy), 10·1years (hypometabolism) to transition from clinically normal to dementia. Finally, CSF p‐tau significantly increased as dementia onset approached. Conclusion Our results reveal the trajectory of biomarkers in sporadic Alzheimer's disease is led by Aβ accumulation, followed by CSF tau change, memory deficits, brain atrophy, hypometabolism, cognitive decline, and lastly CSF p‐tau increase.